Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Universite Claude Bernard – Lyon1

Ecole Normale Superieure De Lyon

Ecole Normale Superieur De Lyon

Els Verhoeyen

François-Loïc Cosset

Francois-Loic Cosset

Caroline Costa

Cecilia Frecha

Christian Buchholz

Dimitri Lavillette

Anais Girard-Gagnepain

Caroline Costa Fejoz

Qi Zhou

Ruben Bender

Thierry Defrance

Floriane Fusil

The invention concerns a multicistronic nucleic acid, in particular an isolated multicistronic nucleic acid, comprising: A) a sequence comprising successively: A1) a sequence encoding the light chain variable domain of an antibody of interest, fused in the frame with A2) a sequence encoding the constant region of the light chain of an immunoglobulin Ig; and B) a sequence comprising successively: B1) a sequence encoding the heavy chain variable domain of said antibody of interest, fused in the frame with B2) a sequence encoding the constant regions of the heavy chain of an immunoglobulin Ig' in secretory form; B3) an intronic sequence of the gene of the heavy chain of said immunoglobulin Ig&#x2032;, said intronic sequence comprising an internal 5&#x2032; splice site enabling the splicing of said intronic sequence B3) and a secretory-specific poly(A) (p AS) signal from the 3&#x2032; terminal exon of said gene; B4) a sequence, in frame with sequence B1), encoding the transmembrane and cytoplasmic domains M1 and M2 of the immunoglobulin Ig&#x2032; BCR, wherein said sequence B4) comprises, between the coding sequences of the M1 and M2 domains, an intronic sequence containing a splice site enabling the splicing of said intronic sequence between the M1 and M2 domains coding sequences; and B5) a membrane-anchored specific poly(A) signal (p AM), after the stop codon of the M2 domain, wherein the multicistronic nucleic acid enables the co-expression of the sequences A and B into separate proteins.

Lentiviral vector expressing membrane-anchored or secreted antibody

The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Nipah virus envelope glycoprotein pseudotyped lentivirus

The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least:

Vector particles for targeting CD34+ cells

The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least:&#x2014;a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or&#x2014;a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.

Lentiviral vectors pseudotyped with mutant BaEV glycoproteins

The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: &#x2014;a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and &#x2014;a second protein which comprises a ligand of the c-Kit receptor.

Growing community of inventors

Lyons, France

Els Verhoeyen